Tuesday, April 29, 2025

Latest

Tetra Bio-Pharma Subsidiary Conducts Financing for Hemp Energy Drink

Tetra Bio-Pharma (TSXV: TBP) announced this morning that a subsidiary of the firm has obtained financing for its Hemp Energy Drink. The financing comes in the form of a convertible debenture to the tune of $3,000,000, which will enable the subsidiary to purchase the full rights to the drink formulation.

With the financing being conducted through that of Tetra Bio-Pharma’s subsidiary, 2714140 Ontario Inc, no details were provided on the financing itself. It’s unclear what portion of the company Tetra would maintain should the full debenture be converted into equity into the currently wholly owned subsidiary. Tetra maintained that 2714140 Ontario Inc remains a fully owned subsidiary of the firm, however it is unclear how long this will hold true for.

Despite the financing, the assets related to Hemp Energy Drink are still for sale. This was originally announced by the firm at the end of August 2019.

We are thrilled to secure financing for the HED business that is, importantly, not dilutive to current Tetra shareholders. We believe the Hemp Energy Drink business can grow much faster in the hands of a team focused on the beverage industry and the use of proceeds from this financing will increase the attractiveness of the asset, and we believe will eventually yield a higher price in the event of a sale.

Guy Chamberland, CEO and Chief Regulatory Officer of Tetra Bio-Pharma Inc

Funding from the convertible note is expected to enable Tetra’s subsidiary to manufacture and distribute the Hemp beverage worldwide while funding ongoing operations.

Tetra Bio-Pharma last traded at $0.20 on the TSX Venture.


Information for this briefing was found via Sedar and Tetra Bio-Pharma. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Bell Q3 Earnings: Massive Impairments. Guidance Cuts. A Mess.

Alamos Gold Q3: Record Revenue & Production Amid Rising Costs

The Junior Mining Market Is Back

Recommended

Germany Looks To Modernize Military Recruitment But Stops Short of Conscription

First Majestic Silver Posts Topline Revenue Of $146.1 Million In Q3 2024

Related News

Drug Trade: The Three Basic Cannabis Health Company Archetypes

The popular belief that cannabis will work its way further into mainstream culture and further...

Saturday, December 21, 2019, 08:00:00 AM

Tetra Bio Pharma Strengthens Product Pipeline Via Co-Development Agreement

Tetra Bio Pharma (TSXV: TBP) has strengthened its product pipeline as of this morning, providing...

Thursday, February 27, 2020, 08:53:49 AM

Tetra Bio Pharma Sees Product Approved For FDA Fast Track Designation Request

Tetra Bio-Pharma (TSXV: TBP) has received a much anticipated response from the US Food and...

Monday, February 3, 2020, 08:47:08 AM

Tetra Bio-Pharma Signs Manufacturing Agreement with Vitiprints

Tetra Bio-Pharma Inc. (TSXV: TBP) has entered into a manufacturing agreement with Vitiprints LLC, which...

Thursday, February 13, 2020, 01:46:29 PM

Tetra Bio-Pharma Releases Update Regarding its Veterinary Clinical Study

Tetra Bio-Pharma Inc (TSXV: TBP) has released an update regarding its clinical study for the...

Wednesday, January 29, 2020, 08:55:32 AM